Jerome M. Fortin
Montreal, QC H3A1A1, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Mutant IDH1 cooperates with NPM1c or FLT3ITD to drive distinct myeloid diseases and molecular outcomes.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: May 16, 2025
Oncogenic IDH1mut drives robust loss of histone acetylation and increases chromatin heterogeneity.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 10, 2025
Cholinergic regulation of thymocyte negative selection.
Journal: Nature immunology
Published: March 19, 2024
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.
Journal: Cancer cell
Published: February 02, 2023
Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 18, 2023
A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation.
Journal: Science (New York, N.Y.)
Published: October 06, 2022
Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma.
Journal: Nature cancer
Published: September 28, 2021
Addition of a carboxy-terminal tail to the normally tailless gonadotropin-releasing hormone receptor impairs fertility in female mice.
Journal: eLife
Published: August 10, 2021
The PTEN and ATM axis controls the G1/S cell cycle checkpoint and tumorigenesis in HER2-positive breast cancer.
Journal: Cell death and differentiation
Published: November 02, 2020
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Journal: Current opinion in biotechnology
Published: August 24, 2020
Last Updated: 09/26/2026